Phage display screening identifies a novel peptide to suppress ovarian cancer cells in vitro and in vivo in mouse models

BMC Cancer

Research Article

Jiali Kang¹  Xiaoxia Wang¹  Wenyan Jiang¹  Cong Zhou²  Wei Wei³ 

[1] Department of Obstetrics and Gynecology, Guangzhou First People’s Hospital, Guangzhou Medical University, 510180, Guangzhou, China;Department of Obstetrics and Gynecology, Maternity and Children’s Healthcare Hospital of Foshan, 528000, Foshan, Guangdong, China;Foshan Hospital of TCM, 52800, Foushan, China;

关键词: Phage display;    Peptide;    Ovarian cancer;    Tumor cell viability;    Invasion;    Adhesion;    Nude mouse tumor model;   

DOI  :  10.1186/s12885-015-1891-8

 received in 2015-07-21, accepted in 2015-11-01,  发布年份 2015

来源: Springer

【 摘 要 】

BackgroundOvarian cancer is a possibly lethal gynecological malignancy and this study utilized phage display technology to screen and identify peptides that specifically bind to ovarian cancer cells and explored the effects of these peptides on ovarian cancer cells in vitro and in vivo.MethodsThe phage displayed peptide library was used to isolate the peptides binding to and internalizing into the ovarian carcinoma cells. Positive phage clones were characterized with DNA sequencing and bioinformatics analysis and then validated with immunofluorescence. Subsequently, the selected peptides were investigated for their cancer-related functions, including cell adhesion, spreading, motility, and invasion in vitro and in vivo.ResultsPeptide1 read as SWQIGGNwas the positive peptide and showed preferential binding to the target cells. Peptide 1 also inhibited cell proliferation, migration, invasion and adhesion of ovarian cancer HO8910 cells in vitro. In vivo, Peptide 1 led to a lower tumorigenicity of HO8910 cells, which was characterized by the inhibitory effect on tumor growth and metastasis of ovarian cells.ConclusionThese studies demonstrate that the phage display-identified tumor cell-binding peptide was able to control ovarian cancer cell viability, migration, invasion, and adhesion capacity in vitro as well as tumor growth and metastasis in vivo. Future studies will be aimed at evaluating the clinical efficacy of the peptide SWQIGGN in ovarian cancer patients.

【 授权许可】

CC BY   
© Zhou et al. 2015